Literature DB >> 23061526

Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis.

S K Murthy1, A H Steinhart, J Tinmouth, P C Austin, N Daneman, G C Nguyen.   

Abstract

BACKGROUND: Clostridium difficile colitis (CDC) is associated with an increased short-term mortality risk in hospitalised ulcerative colitis (UC) patients. We sought to determine whether CDC also impacts long-term risks of adverse health events in this population. AIM: To determine whether CDC also impacts long-term risks of adverse health events in this population.
METHODS: A population-based retrospective cohort study was conducted of UC patients hospitalised in Ontario, Canada between 2002 and 2008. Patients with and without CDC were compared on the rates of adverse health events. The primary outcomes were the 5-year adjusted risks of colectomy and death.
RESULTS: Among 181 patients with CDC and 1835 patients without CDC, the 5-year cumulative colectomy rates were 44% and 33% (P = 0.0052) and the 5-year cumulative mortality rates were 27% and 14% (P < 0.0001) respectively. CDC was associated with a higher adjusted 5-year risk of mortality [adjusted hazard ratio (aHR) 2.40, 95% CI 1.37-4.20], but not of colectomy (aHR 1.18, 95% CI 0.90-1.54). CDC impacted mortality risk both during index hospitalisation (adjusted odds ratio 8.90, 95% CI 2.80-28.3) as well as over 5 years following hospital discharge among patients who recovered from their acute illness (aHR 2.41, 95% CI 1.37-4.22). Colectomy risk was not influenced by CDC in this cohort.
CONCLUSION: Clostridium difficile colitis is associated with increased short-term and long-term mortality risks among hospitalised ulcerative colitis patients. As colectomy risk is not similarly impacted by Clostridium difficile colitis, factors predictive of death among C. difficile-infected ulcerative colitis patients require elucidation.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23061526     DOI: 10.1111/apt.12073

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

Review 1.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

2.  Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.

Authors:  Krista M Newman; Kevin M Rank; Byron P Vaughn; Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-01-19

3.  Dyslipidemia and inflammation in patients with inflammatory bowel disease.

Authors:  Fatih Karaahmet; Omer Basar; Sahin Coban; Ilhami Yuksel
Journal:  Dig Dis Sci       Date:  2013-03-16       Impact factor: 3.199

4.  Clostridium difficile infection worsens the prognosis of ulcerative colitis.

Authors:  María E Negrón; Herman W Barkema; Kevin Rioux; Jeroen De Buck; Sylvia Checkley; Marie-Claude Proulx; Alexandra Frolkis; Paul L Beck; Levinus A Dieleman; Remo Panaccione; Subrata Ghosh; Gilaad G Kaplan
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

Review 5.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 6.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 7.  Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment.

Authors:  Ying M Tang; Christian D Stone
Journal:  Clin J Gastroenterol       Date:  2017-02-16

Review 8.  Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Nancy Fu; Titus Wong
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

9.  Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study.

Authors:  María E Negrón; Ali Rezaie; Herman W Barkema; Kevin Rioux; Jeroen De Buck; Sylvia Checkley; Paul L Beck; Matthew Carroll; Richard N Fedorak; Levinus Dieleman; Remo Panaccione; Subrata Ghosh; Gilaad G Kaplan
Journal:  Am J Gastroenterol       Date:  2016-04-19       Impact factor: 10.864

10.  Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease.

Authors:  Henry A Horton; Seper Dezfoli; Dror Berel; Julianna Hirsch; Andrew Ippoliti; Dermot McGovern; Manreet Kaur; David Shih; Marla Dubinsky; Stephan R Targan; Phillip Fleshner; Eric A Vasiliauskas; Jonathan Grein; Rekha Murthy; Gil Y Melmed
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.